Search the Newsreel

SEC Rejects DeFi Development’s $1B Plan to Acquire Solana, But Vision Remains

The SEC has rejected DeFi Development's $1 billion plan to acquire Solana due to incomplete paperwork and eligibility issues, temporarily halting its ambition to become a major corporate holder of SOL. Despite this setback, the company remains committed to its vision, planning to refile …

How Investors Are Reacting To Peyto Exploration & Development (TSX:PEY) Stronger Year‑Over‑Year Earnings Momentum

Earnings Update: Kolte-Patil Developers Limited (NSE:KOLTEPATIL) Just Reported And Analysts Are Boosting Their Estimates

DeFi Development Corp. to host May 2026 recap and AMA on X Spaces

DeFi Development Corp. will host a May 2026 Business Recap and AMA on June 11, 2026, at 11:00 AM ET via X Spaces. The event will cover treasury operations, capital markets activity, and Solana ecosystem updates, with leadership addressing live questions. This event follows …

What's Going On With Erdene Resource Development Corp Stock Wednesday?

Form 8K DeFi Development Corp For: 12 August By Investing.com

This article from Investing.com announces the filing of a Form 8K by DeFi Development Corp for August 12. It briefly mentions the stock symbol DFDV and its performance, but provides no further details about the content of the 8K filing.

Velocity Financial (VEL) Q2 2026 Earnings Call Transcript

Velocity Financial reported its Q2 2026 earnings, showcasing a total loan portfolio of $7 billion, a 19.2% year-over-year increase, and a diluted book value per share of $18.43. Despite a slight dip in GAAP net income due to a higher effective tax rate, core …

DeFi Development (NASDAQ:DFDV) Announces Earnings Results

DeFi Development (NASDAQ:DFDV) announced its earnings results, reporting a quarterly EPS of negative $0.21, a negative net margin of 1,136.38%, and a positive return on equity of 15.58%. Shares traded near the lower end of their 52-week range, with analysts maintaining a "Moderate Buy" …

Regal Rexnord (RRX) Orders Are Surging, So Why Is Margin Guidance Falling?

Regal Rexnord (NYSE:RRX) just posted its strongest order growth in years in its August 5 earnings release, with a new chief executive at the helm as of July 1. Yet in the same breath, management trimmed its full-year profitability outlook. That contradiction, momentum on …

DeFi Development Corp. (DFDV) grows SOL per share 24% despite Q2 2026 loss

DeFi Development Corp. (DFDV) reported a net loss of $27.287 million in Q2 2026 due to a significant change in digital asset valuation, despite revenue growing 66.9% year-over-year. The company increased its SOL per share (SPS) by 24% to 0.066, holding over 2.3 million …

DeFi Development Buys Back $3.5M Notes at 35% Discount

DeFi Development Corp. announced its Q2 2026 results, reporting a 24% year-over-year increase in SOL per share (SPS) to 0.066 and total SOL and equivalents of 2,311,523. The company also repurchased $3.5 million of its July 2030 convertible notes for $2.3 million, achieving a …

Artelo Biosciences (ARTL) trims liabilities, boosts cash amid $5.4M H1 loss

Artelo Biosciences reported a net loss of $5.4 million for the first half of 2026 but significantly improved its liquidity and balance sheet. The company increased cash and cash equivalents to $4.2 million from $0.6 million at year-end 2025 and reduced total liabilities from …

Tellus (TLS) investor Derrick Dockery files to sell 11,000 shares

Derrick Dockery, an investor in Tellus (TLS), has filed a Form 144 notice to sell 11,000 shares of common stock through Morgan Stanley Smith Barney LLC. The aggregate market value of this planned transaction is $47,737.80, with a proposed sale date of August 12, …

Xilio Therapeutics (NASDAQ:XLO) Announces Earnings Results, Beats Estimates By $0.26 EPS

Xilio Therapeutics (NASDAQ:XLO) announced its earnings results, reporting an adjusted loss of $0.33 per share, which beat analyst estimates by $0.26. The company's revenue of $18.69 million also surpassed expectations, though Xilio Therapeutics remains unprofitable with a negative net margin. Despite institutional investor ownership …

Xilio Therapeutics Releases Q2 2026 Financial Results

Xilio Therapeutics (XLO) reported its Q2 2026 financial results, showing a narrower net loss of $0.33 per share, an 85.3% improvement year-over-year. Revenue significantly increased by 131.2% to $18.7 million compared to Q2 2025. The company specializes in tumor-activated immuno-oncology therapies and continues to …

Goldman Sachs Group (TDAC) discloses 1,056,879 TDAC shares in 7.2% stake

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have reported a beneficial ownership of 1,056,879 Class A ordinary shares in Translational Development Acquisition Corp. (TDAC), representing a 7.2% stake. Both entities hold shared voting and shared dispositive power over …

DeFi Development Corp. Reports Q2 2026 Results, Grows SOL

DeFi Development Corp. (Nasdaq: DFDV) announced its Q2 2026 results, highlighting a 24% year-over-year growth in SOL per share (SPS) to 0.066 and a total of 2,311,523 SOL and equivalents. The company outlined Q3 cost efficiencies, capital structure simplification, and reaffirmed its long-term target …

Transcript : Peyto Exploration & Development Corp., Q2 2026 Earnings Call, Aug 12, 2026

Key Points Interested in Peyto Exploration & Development Corp.? Here are five stocks we like better. Q2 financial performance remained solid: Peyto generated C$228 million in funds from operations, reduced net debt by C$72 million and raised its monthly dividend by 9%, despite seasonal …

Velocity Financial (VEL) Executive VP Jeffrey Taylor Sells 4,330 Shares

Jeffrey Taylor, Executive VP of Velocity Financial (VEL), sold 4,330 shares for approximately $82,530, contributing to a trend of 29 insider sells and no buys over the past year. Despite significant insider selling, Velocity Financial appears "Significantly Undervalued" with a GuruFocus Value of $27.15 …

ArcelorMittal (MT) vs. Microsoft Corporation (MSFT): A Steel Giant Bets Its Future on Azure

On August 3, 2026, Reuters reported that Steelmaker ArcelorMittal S.A. (NYSE:MT) is expanding its partnership with Microsoft Corporation (NASDAQ:MSFT). It is adding Microsoft Fabric, Purview, and Foundry to its Azure-based "Cloud First, Data Centric" strategy, aiming to modernize its IT systems and embed AI …

LifeSci Capital Maintains Eloxx Pharmaceuticals(ELOX.US) With Buy Rating, Maintains Target Price $40

LifeSci Capital has reiterated its Buy rating for Eloxx Pharmaceuticals (ELOX.US) and maintained its target price at $40. This indicates a continued positive outlook from the firm regarding the company's stock performance and valuation.

New City Development Group Clarifies Board and Committee Structure

New City Development Names Li Yang Co-CEO in Leadership Reshuffle

Form 8K Xilio Therapeutics Inc For: 12 August By Investing.com

This article reports on Xilio Therapeutics Inc.'s Form 8K filing for August 12. It notes the company's stock symbol as XLO, which saw a -1.42% change. The content primarily serves as a placeholder or announcement regarding the SEC filing.

Xilio Therapeutics reports Q2 2026: $18.7M collaboration revenue, $6.4M net loss, cash $136.0M

Xilio Therapeutics reported its Q2 2026 financial results, showing $18.7 million in collaboration revenue and a net loss of $6.4 million. The company held $136.0 million in cash and cash equivalents, expecting this to fund operations into Q1 2028. Key business highlights include FDA …

Xilio expects to dose cancer patients with XTX501 in H2 2026

Xilio Therapeutics reported its Q2 2026 financial results and provided updates on its pipeline, including FDA clearance for XTX501, a bispecific PD-1 / masked IL-2, with dosing expected in H2 2026. The company also announced advancing IND-enabling studies for two masked T cell engager …

China Tianbao Warns of Wider Interim Loss on Lower Construction Revenue

Earnings Flash (PEY.TO) Peyto Exploration & Development Corp. Posts Q2 Adjusted EPS C$0.50

Economists urge Govt: Check the fine print of US$750M steel plant revival

Economists are cautioning the Trinidad and Tobago government to thoroughly examine the details of the proposed US$750 million revival of the former ArcelorMittal steel plant. While the project could boost the economy through foreign exchange generation and job creation, experts like Professor Patrick Watson …

Wasatch Advisors LP Lowers Holdings in Five Below, Inc. $FIVE

Wasatch Advisors LP significantly reduced its stake in Five Below, Inc. by 60.2% in the second quarter of 2026, selling 492,490 shares and retaining 325,892 shares valued at $58.6 million. Despite this reduction and some recent analyst downgrades, the overall analyst sentiment remains a …

Eloxx Plans Phase 2b Alport Trial in Q3 After ~$66M Offering

Eloxx Pharmaceuticals reported its second-quarter 2026 financial results, highlighting a significant strengthening of its capital position with $62.0 million in cash after a $66.0 million public offering. The company plans to initiate a Phase 2b clinical trial for exaluren in nonsense mutation Alport syndrome …

Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Eloxx Pharmaceuticals reported strong second-quarter 2026 financial results, highlighted by a $66.0 million public offering and uplisting to Nasdaq, significantly bolstering its balance sheet. The company is advancing its lead product candidate, exaluren, with a Phase 2b clinical trial for nonsense mutation Alport syndrome …

Kinetic Development Sets Board Meeting to Review Interim Results and Dividend

William Blair Maintains NioCorp Developments(NB.US) With Buy Rating

William Blair has reiterated its Buy rating on NioCorp Developments (NB.US). This indicates a continued positive outlook from the firm regarding NioCorp Developments' stock performance and prospects.

Lodha Developers shares decline 2.02% to Rs 1,187.50

Medical Developments International Sets Date for FY26 Results and Investor Webcast